Get the Stockscreener App
0.458
5.05%
+0.022
After Hours:
.458
Evoke Pharma Inc stock is currently priced at $0.458, with a 24-hour trading volume of 8,747.
It has seen a +5.05% increased in the last 24 hours and a -24.26% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.439 pivot point. If it approaches the $0.463 resistance level, significant changes may occur.
Previous Close:
$0.436
Open:
$0.461
24h Volume:
8,747
Market Cap:
$3.88M
Revenue:
$5.18M
Net Income/Loss:
$-7.79M
P/E Ratio:
-0.1941
EPS:
-2.36
Net Cash Flow:
$-4.99M
1W Performance:
-2.24%
1M Performance:
-24.26%
6M Performance:
-60.17%
1Y Performance:
-75.77%
1D Range:
$0.437
$0.48
52W Range:
$0.4159
$2.3999
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858 345 1494
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
GlobeNewswire Inc.
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
GlobeNewswire Inc.
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
GlobeNewswire Inc.
Evoke Pharma Announces Closing of $7.5 Million Public Offering
GlobeNewswire Inc.
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
GlobeNewswire Inc.
Evoke Pharma Inc Stock (EVOK) Financials Data
Evoke Pharma Inc (EVOK) Revenue 2024
EVOK reported a revenue (TTM) of $5.18 million for the quarter ending December 31, 2023, a +106.51% rise year-over-year.
Evoke Pharma Inc (EVOK) Net Income 2024
EVOK net income (TTM) was -$7.79 million for the quarter ending December 31, 2023, a +5.25% increase year-over-year.
Evoke Pharma Inc (EVOK) Cash Flow 2024
EVOK recorded a free cash flow (TTM) of -$4.99 million for the quarter ending December 31, 2023, a +24.42% increase year-over-year.
Evoke Pharma Inc (EVOK) Earnings per Share 2024
EVOK earnings per share (TTM) was -$2.33 for the quarter ending December 31, 2023, a +11.74% growth year-over-year.
About Evoke Pharma Inc
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
1.69%
1.28%
Cap:
|
Volume (24h):